Acute pulmonary hypertension, high pressure in the lung blood circulation, is a life-threatening condition that occurs in a large number of different critical illnesses. In the Covid-19 pandemic it has certainly shown its high death toll.
The method currently used in an effort to treat the life-threatening condition is to let the patient inhale nitric oxide gas. But this method has major shortcomings. This is where Supernitro comes in with its unique and efficient properties.
The company behind
Attgeno AB, home of Supernitro, is a Swedish pharmaceutical company founded to develop and commercialize the discovery of completely new methods to provide innovative and efficient nitric oxide-donating drugs.